Nkarta Inc
NEWS
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
Silicon Valley Bank was one of the primary lending institutions for biotech. A year after its demise, the industry has recovered, but lessons have been learned and scars remain.
A roundup of last week’s top clinical trial updates and news.
Nkarta announced that two of its therapies have shown complete remission in patients with blood cancer. These results are the latest development in the treatment of difficult-to-treat blood cancers.
First Moscow State Medical University has paused recruiting new patients for its ongoing clinical trials following a disruption in the university’s ability to receive clinical trial samples.
Protein degradation, cell therapy, synergistic combinations and changes in personalized cancer therapies will drive the next generation of therapeutics...
Biopharmaceutical company CRISPR Therapeutics has entered into a strategic research, development and commercialization partnership with cancer-focused Nkarta.
Nkarta has treated its first patient in the first-in-human Phase I clinical trial of NKX101, an investigational immunotherapy designed to treat relapsed/refractory acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes.
JOBS
IN THE PRESS